Pharmaceutical composition for the treatment of diabetes

Pharmaceutical composition for the treatment of diabetes

A pharmaceutical composition which comprises an insulin sensitizer in combination with an anorectic, which is useful as an agent for preventing or treating diabetes.

Agent for treating high-risk impaired glucose tolerance

The present invention discloses an α-glucosidase inhibitor for prevention of transition from high-risk IGT to diabetes mellitus, for prophylaxis of diabetes mellitus, as well as for treating high-risk IGT.

5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity

Pharmaceutical composition

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Oxazolidinedione derivatives, their production and use

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Pharmaceutical composition

Oxazole derivatives, their production and use

A novel compound of the formula:wherein R1 is a halogen atom, an optionally substituted heterocyclic, hydroxy, thiol or amino group; A is an optionally substituted acyl group, an optionally substituted heterocyclic group, an optionally substituted hydroxy group, or an optionally esterified or amidated carboxy group; B is an optionally substituted aromatic group; Y is a divalent aliphatic hydrocarbon group, or a salt thereof, which have an excellent insulin secertion-promoting and blood sugar-depressing effect, and useful in agents for diabetes.

Retinoid-related receptor function regulating agent

1,3-Azole derivatives, pharmaceutical compositions thereof and methods for regulating the function of retinoid-related receptors with 1,3-azole derivatives are disclosed. Such regulation may be useful for preventing or treating diabetes, preventing or treating hyperlipidemia, preventing or treating impaired glucose tolerance (IGT) or for preventing transition from impaired glucose tolerance to diabetes.

Pharmaceutical composition

Drugs containing combined active ingredients

A pharmaceutical agent comprising only an α-glucosidase inhibitor in combination with a non-sulfonylurea insulinsecretagogue as active ingredients is useful as an agent for the prophylaxis or treatment of diabetes and the like.

Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity

5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Oxyiminoalkanoic acid derivatives

A compound represented by the formula:wherein R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X is a bond, -CO-, -CH(OH)- or a group represented by -NR6- wherein R6 is a hydrogen atom or an optionally substituted alkyl group; n is an integer of 1 to 3; Y is an oxygen atom, a sulfur atom, -SO-, -SO2- or a group represented by -NR7- wherein R7 is a hydrogen atom or an optionally alkyl group; ring A is a benzene ring optionally having additional one to three substituents; p is an integer of 1 to 8; R2 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; q is an integer of 0 to 6; m is 0 or 1; R3 is a hydroxy group, OR8 (R8 is an optionally substituted hydrocarbon group.) or NR9R10 (R9 and R10 are the same or different groups which are selected from a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted ...

Oxyiminoalkanoic acid derivatives

To provide a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the prevention or treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance. A compound represented by the formula: wherein R1is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X is a bond, —CO—, —CH(OH)— or a group represented by —NR6— wherein R6is a hydrogen atom or an optionally substituted alkyl group; n is an integer of 1 to 3; Y is an oxygen atom, a sulfur atom, —SO—, —SO2— or a group represented by —NR7— wherein R7is a hydrogen atom or an optionally alkyl group; ring A is a benzene ring optionally having additional one to three substituents; p is an integer of 1 to 8; R2is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; q is an integer of 0 to 6; m is 0 or 1; R3is a hydroxy group, OR8 ...

UNDERWATER MINER CUTTER HEAD, UNDERWATER MINER, AND UNDERWATER MINING SYSTEM

Provided is an underwater miner cutter head () attached to an underwater miner disposed on a seabed and configured to excavate the seabed, the cutter head including cylindrical cutter drums () disposed on respective sides defining a regular polygon in plan view, having bits () on the outer circumferential surfaces thereof, and configured to rotate around corresponding first rotational axes by first driving sources; and an intake () disposed at a center part of the regular polygon and configured to receive muck excavated with the bits (), wherein rotating directions of the cutter drums () are set such that the bits () sequentially move toward the intake (). 1. An underwater miner cutter head attached to an underwater miner disposed on a seabed and configured to excavate the seabed , the cutter head comprising:cylindrical cutter drums disposed on respective sides defining a regular polygon in plan view, having bits provided on outer circumferential surfaces thereof, and configured to rotate around corresponding first rotational axes by first driving sources; andan intake disposed at a center part of the regular polygon and configured to receive muck excavated with the bits,wherein rotating directions of the cutter drums are set such that the bits sequentially move toward the intake.2. The underwater miner cutter head according to claim 1 , wherein the cutter drums are attached via a cutter support arm claim 1 , and a plate-like turning base rotated by a second driving source around a second rotational axis passing through the center of the regular polygon is provided.3. The underwater miner cutter head according to claim 2 , further comprising:a third driving source configured to slide the turning base in a direction orthogonal to the second rotational axis.4. An underwater miner comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the underwater miner cutter head according to .'}5. An underwater mining system comprising:{'claim-ref': {'@idref': 'CLM-00004', ...

Underwater miner cutter head, underwater miner, and underwater mining system

Provided is an underwater miner cutter head (20) attached to an underwater miner disposed on a seabed and configured to excavate the seabed, the cutter head including cylindrical cutter drums (21) disposed on respective sides defining a regular polygon in plan view, having bits (26) on the outer circumferential surfaces thereof, and configured to rotate around corresponding first rotational axes by first driving sources; and an intake (28) disposed at a center part of the regular polygon and configured to receive muck excavated with the bits (26), wherein rotating directions of the cutter drums (21) are set such that the bits (26) sequentially move toward the intake (28).

Function regulator for retinoid relative receptor

The present invention provides a retinoid-related receptor (except retinoic acid receptors) function regulating agent comprising a compound represented by the formula: wherein one of R1 and R2 is an optionally substituted monocyclic aromatic hydrocarbon group or an optionally substituted monocyclic aromatic heterocyclic group containing one heteroatom, and the other is a hydrogen atom and the like; B is a 5- or 6-membered heterocycle (except 1,3-azole); A is an optionally substituted aromatic hydrocarbon group or an optionally substituted aromatic heterocyclic group; and R3 is a hydrogen atom and the like, or a salt thereof, which is useful as an agent for the prophylaxis or treatment of diabetes mellitus, hyperlipidemia, impaired glucose tolerance or the like.

Oxazole derivatives, their production and use

A novel compound of the formula:wherein R1 is a halogen atom, an optionally substituted heterocyclic, hydroxy, thiol or amino group; A is an optionally substituted acyl group, an optionally substituted heterocyclic group, an optionally substituted hydroxy group, or an optionally esterified or amidated carboxy group; B is an optionally substituted aromatic group; Y is a divalent aliphatic hydrocarbon group, or a salt thereof, which have an excellent insulin secertion-promoting and blood sugar-depressing effect, and useful in agents for diabetes.

Alkanoic acid derivatives process for their production and use thereof

An alkanoic acid derivative useful as a prophylactic or therapeutic agent of diabetes mellitus, hyperlipidemia, impaired glucose tolerance and the like can be provided by a compound represented by the formula wherein R 1 is an optionally substituted 5-membered aromatic heterocyclic group; X is a bond and the like; Q is a divalent hydrocarbon group having 1 to 20 carbon atoms; Y is a bond and the like, ring A is an aromatic ring optionally further having 1 to 3 substituents; Z is —(CH 2 ) n —Z 1 — (n is an integer of 1 to 8 and Z 1 is an oxygen atom and the like) and the like; ring B is a pyridine ring optionally further having 1 to 3 substituents, and the like; U is a bond and the like; W is a divalent hydrocarbon group having 1 to 20 carbon atoms; and R 3 is —OH and the like, provided that, when ring B is a benzene ring optionally further having 1 to 3 substituents, U should be a bond, or a salt thereof.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity

A compound of formula (I) F wherein R¹ represents a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; x represents a bond, an oxygen atom, a sulfur atom, or a group of the formula: -CO-, -CS-, -CR⁴(OR⁵)- or -NR⁶- wherein each of R⁴ and R⁶ represents a hydrogen atom or a hydrocarbon group which may be stubstituted, R⁵ represents a hydrogen atom or a protective group for a hydroxyl group; m represents an integer of 0 to 3; Y represents an oxygen atom, a sulfur atom, or a group of the formula: -SO-, -SO₂-, -NR₇-, -CONR₇- or -NR⁷CO- wherein R⁷ represents a hydrogen atom or a hydrocarbon group which may be substituted; ring A represents an aromatic ring which may further have 1 to 3 substituents; n represents an integer of 1 to 8; ring B represents a nitrogen-containing 5-membered hetero ring which may further be substituted ...

Alkanoic acid derivatives process for their production and use thereof

An alkanoic acid derivative useful as a prophylactic or therapeutic agent of diabetes mellitus, hyperlipidemia, impaired glucose tolerance and the like can be provided by a compound represented by the formula wherein R¹ is an optionally substituted 5-membered aromatic heterocyclic group; X is a bond and the like; Q is a divalent hydrocarbon group having 1 to 20 carbon atoms; Y is a bond and the like; ring A is an aromatic ring optionally further having 1 to 3 substituents; Z is -(CH₂)_n-Z¹-(n is an integer of 1 to 8 and Z¹ is an oxygen atom and the like) and the like; ring B is a pyridine ring optionally further having 1 to 3 substituents, and the like; U is a bond and the like; W is a divalent hydrocarbon group having 1 to 20 carbon atoms; and R³ is -OH and the like, provided that, when ring B is a benzene ring optionally further having 1 to 3 substituents, U should be a bond, or a salt thereof.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

PHARMACEUTICAL COMPOSITION

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Five-membered heterocyclic alkanoic acid derivative

The present invention relates to a compound represented by the formula wherein R 1 is an optionally substituted 5-membered heterocyclic group; X is a bond etc.; Q is a divalent hydrocarbon group having 1 to 20 carbon atoms; Y is a bond etc.; ring A is an aromatic ring optionally further having 1 to 3 substituents; Z is —(CH 2 ) n —Z 1 — (n is an integer of 0 to 8 and Z 1 is a bond etc.) and the like; ring B is a 5-membered heterocycle optionally further having 1 to 3 substituents; W is a divalent saturated hydrocarbon group having 1 to 20 carbon atoms; R 2 is —OH etc., or a salt thereof. A pharmaceutical composition containing this compound is useful as a prophylactic or therapeutic agent of diseases such as diabetes mellitus and the like.

Five-membered heterocyclic compounds

The present invention provides a compound represented by the formula: wherein R1 is an optionally substituted 5-membered heterocyclic group; X, Y and V are the same or different and each is a bond, an oxygen atom, a sulfur atom and the like; Q is a divalent hydrocarbon group having 1 to 20 carbon atoms; ring A is an aromatic ring optionally further having 1 to 3 substituents; Z is —(CH2)n-Z1- or -Z1-(CH2)n— (n is an integer of 0 to 8, Z1 is a bond, an oxygen atom, a sulfur atom and the like); ring B is a nitrogen-containing heterocycle optionally further having 1 to 3 substituents; W is a bond or a divalent hydrocarbon group having 1 to 20 carbon atoms; R2 is a hydrogen atom, a cyano group, —PO(OR9)(OR10) (R9 and R10 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, and R9 and R10 are optionally bonded to form an optionally substituted ring) and the like, or a salt thereof, which has a superior adipose tissue weight decreasing action, ...

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Agent for improving acidosis

An agent for improving ketosis which comprises an insulin sensitizer, which has an excellent action and low toxicity.

Function regulator for retinoid relative receptor

The present invention provides a retinoid-related receptor (except retinoic acid receptors) function regulating agent comprising a compound represented by the formula: wherein one of R¹ and R² is an optionally substituted monocyclic aromatic hydrocarbon group or an optionally substituted monocyclic aromatic heterocyclic group containing one heteroatom, and the other is a hydrogen atom and the like; B is a 5- or 6-membered heterocycle (except 1,3-azole); A is an optionally substituted aromatic hydrocarbon group or an optionally substituted aromatic heterocyclic group; and R³ is a hydrogen atom and the like, or a salt thereof, which is useful as an agent for the prophylaxis or treatment of diabetes mellitus, hyperlipidemia, impaired glucose tolerance or the like.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in he mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Pharmaceutical composition

A pharmaceutical composition which comprises an insulin sensitizer in combination with an anorectic, which is useful as an agent for preventing or treating diabetes.

Five-membered heterocyclic alkanoic acid derivative

The present invention relates to a compound represented by the formula wherein R1 is an optionally substituted 5-membered heterocyclic group; X is a bond etc.; Q is a divalent hydrocarbon group having 1 to 20 carbon atoms; Y is a bond etc.; ring A is an aromatic ring optionally further having 1 to 3 substituents; Z is —(CH2)n—Z1— (n is an integer of 0 to 8 and Z1 is a bond etc.) and the like; ring B is a 5-membered heterocycle optionally further having 1 to 3 substituents; W is a divalent saturated hydrocarbon group having 1 to 20 carbon atoms; R2 is —OH etc., or a salt thereof. A pharmaceutical composition containing this compound is useful as a prophylactic or therapeutic agent of diseases such as diabetes mellitus and the like.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Body weight gain inhibitors

An agent for inhibiting body weight gain derived from a PPARγ agonist-like substance, which contains a PPARδ agonist-like substance, is useful for the treatment of diabetes and the like.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Tnf-alpha inhibitors

There is provided a TNF-α inhibitor comprising at least one compound selected from cerivastatin, atorvastatin, simvastatin, pravastatin, itavastatin and (+)-(3R, 5S)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonylamino) pyrimidin-5-yl]-3,5-dihydroxy-6 (E)-heptenoic acid, or a salt thereof, which is excellent in the preventing and treating effects to TNF-α -associated diseases such as inflammatory disease and has the sufficiently excellent nature as a medicine, such as absence of side effect.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Oxyiminoalkanoic acid derivatives

To provide a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the prevention or treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance. A compound represented by the formula: wherein R¹ is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X is a bond, -CO-, -CH(OH)- or a group represented by -NR⁶- wherein R⁶ is a hydrogen atom or an optionally substituted alkyl group; n is an integer of 1 to 3; Y is an oxygen atom, a sulfur atom, -SO-, -SO₂- or a group represented by -NR⁷- wherein R⁷ is a hydrogen atom or an optionally alkyl group; ring A is a benzene ring optionally having additional one to three substituents; p is an integer of 1 to 8; R² is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic ...

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity

This invention provides a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Agent for improving acidosis

An agent for improving ketosis which comprises an insulin sensitizer, which has an excellent action and low toxicity.

1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity

A compound represented by the formula (1) wherein ring A is a ring optionally having 1 to 3 substituents; ring B is a 1,2-azole ring which may further have 1 to 3 substituents; Xa, Xb and Xc are the same or different and each is a bond, —O—, —S— and the like; Ya is a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; Yb and Yc are the same or different and each is a bond or a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; ring C is a monocyclic aromatic ring which may further have 1 to 3 substituents; and R represents —OR4 (R4 is hydrogen atom or optionally substituted hydrocarbon group) and the like, or a salt thereof or a prodrug thereof is useful as an agent for the prophylaxis or treatment of diabetes and the like.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Screening method

The present invention provides a method of screening for an agent for the treatment of human diabetes mellitus, which comprises administering a test compound to a diabetes mellitus model non-human mammal, and selecting a compound that causes a decrease of not less than 0.5% in a glycated hemoglobin value after administration.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Five-membered heterocyclic compounds

The present invention provides a compound represented by the formula: wherein R¹ is an optionally substituted 5-membered heterocyclic group; X, Y and V are the same or different and each is a bond, an oxygen atom, a sulfur atom and the like; Q is a divalent hydrocarbon group having 1 to 20 carbon atoms; ring A is an aromatic ring optionally further having 1 to 3 substituents; Z is -(CH₂)_n-Z¹- or -Z¹-(CH₂)_n- (n is an integer of 0 to 8, Z¹ is a bond, an oxygen atom, a sulfur atom and the like); ring B is a nitrogen-containing heterocycle optionally further having 1 to 3 substituents; W is a bond or a divalent hydrocarbon group having 1 to 20 carbon atoms; R² is a hydrogen atom, a cyano group, -PO(OR⁹)(OR¹⁰) (R⁹ and R¹⁰ are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, and R⁹ and R^{10 ...}

Agent for improving ketosis

An agent for improving ketosis which comprises an insulin sensitizer, which has an excellent action and low toxicity.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Drug comprising combination

A TNF-α inhibitor comprising an insulin sensitizer in combination with an HMG-CoA reductase inhibitor is useful as an agent for the prophylaxis or treatment of an inflammatory disease and the like.

AGENTS TO TREAT GLUCOSE RESISTANCE THAT IS RISK OF HIGH DAMAGED

Drugs containing combined active ingredients

Drugs containing, as the active ingredients, exclusively a combination of an α-glucosidase inhibitor with a non-sulfonylurea insulin secretion promoter which are useful as preventives and remedies for diabetes, etc.

Combination of insulin sensitizer with anorectic for treating or preventing diabetes

A pharmaceutical composition which comprises an insulin sensitizer in combination with an anorectic, which is useful as an agent for preventing or treating diabetes.

5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity

A COMPOUND OF THE FORMULA:R1-X-(CH2)m-Y-A-(CH2)n-NB-W-(C=0)-R3(I)WHEREIN R1 REPRESENTS A HYDROCARBON GROUP WHICH MAY BE SUBSTITUTED OR A HETEROCYCLIC GROUP WHICH MAY BE SUBSTITUTED;X REPRESENTS A BOND, AN OXYGEN ATOM, A SULFUR ATOM, OR A GROUP OF THE FORMULA: -CO-, -CS-, -CR4(OR5)- OR -NR6- WHEREIN EACH OF R4 AND R6 REPRESENTS A HYDROGEN ATOM OR A HYDROCARBON GROUP WHICH MAY BE SUBSTITUTED, R5 REPRESENTS A HYDROGEN ATOM OR A PROTECTIVE GROUP FOR A HYDROXYL GROUP;m REPRESENTS AN INTEGER OF 0 TO 3;Y REPRESENTS AN OXYGEN ATOM, A SULFUR ATOM, OR A GROUP OF THE FORMULA : -SO-, -SO2-, -NR7-, -CONR7- OR -NR7CO- WHEREIN R7 REPRESENTS A HYDROGEN ATOM OR A HYDROCARBON GROUP WHICH MAY BE SUBSTITUTED;RING A REPRESENTS AN AROMATIC RING WHICH MAY FURTHER HAVE 1 TO 3 SUBSTITUENTS;n REPRESENTS AN INTEGER OF 1 TO 8; RING B REPRESENTS A NITROGEN-CONTAINING 5-MEMBERED HETERO RING WHICH MAY FURTHER BE SUBSTITUTED BY AN ALKYL GROUP;X1 REPRESENTS A BOND, AN OXYGEN ATOM, A SULFUR ATOM,OR A GROUP OF THE FORMULA: -SO-, -SO2-, -O-SO2- OR -NR16- WHEREIN R16 REPRESENTS A HYDROGEN ATOM OR A HYDROCARBON GROUP WHICH MAY BE SUBSTITUTED;R2 REPRESENTS A HYDROGEN ATOM, A HYDROCARBON GROUP WHICH MAY BE SUBSTITUTED OR A HETEROCYCLIC GROUP WHICH MAY BE SUBSTITUTED;W REPRESENTS A BOND OR A DIVALENT HYDROCARBON RESIDUE HAVING 1 TO 20 CARBON ATOMS;R3 REPRESENTS A GROUP OF THE FORMULA: -OR8 (R8 REPRESENTS A HYDROGEN ATOM OR A HYDROCARBON GROUP WHICH MAY BE SUBSTITUTED) OR -NR9-R10 ( EACH OF R9 AND R10 , WHETHER IDENTICAL OR NOT, REPRESENTSA HYDROGEN ATOM, A HYDROCARBON GROUP WHICH MAY BE SUBSTITUTED, A HETEROCYCLIC GROUP WHICH MAY BE SUBSTITUTED, OR AN ACYL GROUP WHICH MAY BE SUBSTITUTED; R9 AND R10 MAY BIND TOGETHER TO FORM A RING); PROVIDED THAT R1 IS A HETEROCYCLIC GROUP WHICH MAY BE SUBSTITUTED OR R2 IS AN AROMATIC HYDROCARBON GROUP WHICH MAY BE SUBSTITUTED OR A HETEROCYCLIC GROUP WHICH MAY BE SUBSTITUTED, WHEN RING A IS A BENZENE RING WHICH MAY BE SUBSTITUTED, AND Y IS AN OXYGEN ATOM, A SULFUR ATOM,

1,2-azole derivatives with hypoglycemic and hypolipidemic activity

Use of insulin sensitisers for improving ketosis

An agent for improving ketosis which comprises an insulin sensitizer, which has an excellent action and low toxicity.

Pharmaceutical compositions comprising pioglitazone and an insulin secretion enhancer

Disclosed is a pharmaceutical composition which comprises pioglitazone or a pharmacologically acceptable salt thereof in combination with an insulin secretion enhancer and which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Alkanoic acid derivatives, process for their production and use thereof

Alkanoic acid derivatives represented by the general formula (I) or salts thereof, useful as preventive and/or therapeutic agents for diabetes, hyperlipidemia, impaired glucose tolerance, and so on: (I) wherein R1 is an optionally substituted five-membered aromatic heterocyclic group; X is a free valency or the like; Q is a divalent hydrocarbon group containing 1 to 20 carbon atoms; Y is a free valency or the like; A is an aromatic ring which may have one to three substituents; Z is -(CH¿2)n-Z?1- (wherein n is an integer of 1 to 8; and Z1 is oxygen or the like) or the like; B is an optionally mono- to tri-substituted pyridine ring or the like; U is a free valency or the like; W is a divalent hydrocarbon group containing 1 to 20 carbon atoms; and R3 is -OH or the like, with the proviso that when B is an optionally mono- to tri-substituted benzene ring, U is a free valency.

Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity.

Pharmaceutical composition

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Pharmaceutical composition

Alkoxyiminoalkanoic acid derivatives

Compounds of general formula (I) or salts thereof are useful as preventive or therapeutic agents for diabetes and so on wherein R1 is an optionally substituted hydrocarbon group or the like; X is a free valency or the like; Y is oxygen or the like; A is a heterocycle or the like; R2 is hydrogen or the like; R3 is OR9 or the like; and R4 and R5 are each hydrogen or the like, with the provisos that when A is optionally substituted indole, Y is not oxygen or sulfur, that when Y is oxygen, sulfur, -SO-, -SO2-, or -NR8-, A is not an optionally substituted benzene ring, and that when Y is oxygen and A is an optionally substituted, 4-pyrone, 4-pyridone, or pyridine N-oxide ring, R2 is not a thiazolyl or thiadiazolyl group substituted with optionally protected amino.

Pharmaceutical composition for the treatment of diabetes

Anti-inflammatory agent

Alkanoic acid derivatives, process for their production and use thereof

An alkanoic acid derivative useful as a prophylactic or therapeutic agent of diabetes mellitus, hyperlipidemia, impaired glucose tolerance and the like can be provided by a compound represented by the formula wherein R 1 is an optionally substituted 5-membered aromatic heterocyclic group; X is a bond and the like; Q is a divalent hydrocarbon group having 1 to 20 carbon atoms; Y is a bond and the like; ring A is an aromatic ring optionally further having 1 to 3 substituents; Z is -(CH 2 ) n -Z 1 - (n is an integer of 1 to 8 and Z 1 is an oxygen atom and the like) and the like; ring B is a pyridine ring optionally further having 1 to 3 substituents, and the like; U is a bond and the like; W is a divalent hydrocarbon group having 1 to 20 carbon atoms; and R 3 is -OH and the like, provided that, when ring B is a benzene ring optionally further having 1 to 3 substituents, U should be a bond, or a salt thereof.

Underwater miner cutter head, underwater miner, and underwater mining system

Disclosed is a cutter head (20) for underwater mining machines which is incorporated into an underwater mining machine located on an underwater bottom to excavate the underwater bottom. The cutter head (20) includes a cylindrical cutter drum (21) and a suction port (28). The cutter drum (21) is disposed on each of the sides that form a regular polygon in a plan view and provided on the outer circumferential surface thereof with bits (26). The cutter drum is rotated by a first drive source around a first rotating axis. The suction port (28) is disposed at the central portion of the regular polygon to receive the excavated muck that is excavated with the bits (26). The cutter drum (21) is set in such a rotational direction that allows the bits (26) to sequentially advance toward the suction port (28).

Agent for improving ketosis

Cutter head for underwater mining machine, underwater mining machine, and underwater mining system

Disclosed is a cutter head (20) for underwater mining machines which is incorporated into an underwater mining machine located on an underwater bottom to excavate the underwater bottom. The cutter head (20) includes a cylindrical cutter drum (21) and a suction port (28). The cutter drum (21) is disposed on each of the sides that form a regular polygon in a plan view and provided on the outer circumferential surface thereof with bits (26). The cutter drum is rotated by a first drive source around a first rotating axis. The suction port (28) is disposed at the central portion of the regular polygon to receive the excavated muck that is excavated with the bits (26). The cutter drum (21) is set in such a rotational direction that allows the bits (26) to sequentially advance toward the suction port (28).

Thiazolidinedione derivatives, their production and use

Pharmaceutical composition comprising pioglitazone and glimepiride for use in treatment of diabetes

Compound, pharmaceutical composition, agent to control retinoid-related receptors, diabetes mellitus prevention and therapy processes, hyperlipemia prevention and therapy, to enhance insulin sensitivity, to improve insulin resistance, prevention and therapy of impaired glucose tolerance, prevention and therapy of an inflammatory disease, prevention of arterial sclerosis, and, use of the compound

"COMPOSTO, COMPOSIçãO FARMACêUTICA, AGENTE PARA CONTROLAR OS RECEPTORES RELACIONADOS COM A RETINóIDE, PROCESSOS DE PREVENçãO E TERAPIA DA DIABETES MELLITUS, DE PREVENçãO E TERAPIA DA HIPERLIPEMIA, PARA ACENTUAR UMA SENSIBILIDADE à INSULINA, PARA MELHORAR UMA RESISTêNCIA à INSULINA, DE PREVENçãO E TERAPIA DA TOLERâNCIA à GLICOSE PREJUDICADA, DE PREVENçãO E TERAPIA DE UMA DOENçA INFLAMATóRIA, DE PREVENçãO E TERAPIA DE UMA ESCLEROSE ARTERIAL, E, USO DO COMPOSTO" Fornecer um novo derivado do ácido oxiiminoalcanóico que tenha excelente ações hipoglicêmicas e hipolipidêmicas e que seja usado para a prevenção ou tratamento de diabetes mellitus, hiperlipemia, insensibilidade à insulina, resistência à insulina e tolerância à glicose prejudicada. Um composto representado pela fórmula (a) em que R¹ é um grupo hidrocarboneto opcionalmente substituído ou um grupo heterocíclico opcionalmente substituído; X é uma ligação, -CO-, -CH(OH)- ou um grupo representado por -NR^ 6^- em que R^ 6^ é um átomo de hidrogênio ou um grupo alquila opcionalmente substituído; n é um número inteiro de 1 a 3; Y é um átomo de oxigênio, um átomo de enxofre, -SO-, -SO~ 2~- ou um grupo representado por -NR^ 7^- em que R^ 7^ é um átomo de hidrogênio ou um grupo alquila opcionalmente; o anel A é um anel de benzeno tendo opcionalmente de um a três substituintes adicionais; p é um número inteiro de 1 a 8; R~ 2~ é um átomo de hidrogênio, um grupo hidrocarboneto opcionalmente substituído ou um grupo heterocíclico opcionalmente substituído; q é um número inteiro de 0 a 6; m é 0 ou 1; R³ é um grupo hidróxi, OR^ 8^ (R^ 8^ é um grupo hidrocarboneto opcionalmente substituído) ou NR^ 9^R^ 10^ (R^ 9^ e R^ 10^ são os mesmos grupos ou grupos diferentes que são selecionados de um átomo de hidrogênio, um grupo hidrocarboneto opcionalmente substituído, um grupo heterocíclico opcionalmente substituído ou um grupo acila opcionalmente substituído ou R^ 9^ e R^ 10^ combinam-se juntos para formar um anel); R^ 4^ e R^ 5^ ...

Use of insulin sensitisers for improving ketosis

An agent for improving ketosis which comprises an insulin sensitizer, which has an excellent action and low toxicity.

Function regulator for retinoid relative receptor

A function regulator for retinoid relative receptors (excluding retionic acid receptors) which contains a compound represented by the general formula (I) (wherein one of R1 and R2 represents an optionally substituted, monocyclic aromatic hydrocarbon group or an optionally substituted, monocyclic aromatic heterocyclic group containing one heteroatom and the other represents hydrogen, etc.; B represents a 5- or 6-membered heterocycle (excluding 1,3-azole); A represents an optionally substituted aromatic hydrocarbon group or an optionally substituted aromatic heterocyclic group; and R3 represents hydrogen, etc.) or a salt thereof. The regulator is useful as a preventive/remedy for diabetes, hyperlipidemia, impaired glucose tolerance, etc.

Oxazolidinedioe derivatives their production and use

Drugs containing combined active ingredients

Drugs containing, as the active ingredients, exclusively a combination of an α-glucosidase inhibitor with a non-sulfonylurea insulin secretion promoter which are useful as preventives and remedies for diabetes, etc.

Pharmaceutical composition comprising pioglitazone and glimepiride for use in treatment of diabetes

5-membered N-heterocyclic compounds with hypolglycemic and hypolipidemic activity

Compounds of formula (I), wherein: R1 is an optionally substituted hydrocarbon or heterocyclic group, X is a bond, an oxygen, a sulphur, -CO-, -CS-, -CR4(OR5)-, or -NR6-, m is 0-3, Y is oxygen, sulphur, -SO-, -SO2-, -NR7-, -CONR7-, or -NR7CO- , A is an optionally substituted aromatic ring, n is 1-8, B is a nitrogen containing 5 membered hetero ring that may be substituted by alkyl, R2 is hydrogen, or optionally substituted hydrocarbon or heterocycle, W is a bond or hydrocarbon, and R3 is -OR8, or -NR9R10. The compounds are used in the manufacture of medicaments with hypoglycemic and hypolipidemic activity.

Oxazolidinedione derivatives, pharmaceutical preparations containing such derivatives, and their use

Agent for treating high-risk impaired glucose tolerance

Oxazolidinedione derivatives, their preparation and use

Thiazolidinedione derivatives, their production and use

A 2,4-thiazolidinedione derivative of formula (I), wherein R is an optionally substituted hydrocarbon group or heterocyclic group which may be attached through a hydrocarbon chain; n is 0 or 1; X is CH or N; Y is a bivalent hydrocarbon group; R1 and R2 are the same or different and are a hydrogen atom, a halogen atom, an optionally substituted hydroxyl group or an optionally substituted hydrocarbon group, and either R1 or R2 and a part of Y may be linked together to form a ring; and L and M are a hydrogen atom, or L and M are linked together to form a bond; or a salt thereof. A pharmaceutical composition comprising the compound (I) and a process for producing the compound (I) are also provided.

Vektökningsinhibitorer

Drugs containing combined active ingredients

A pharmaceutical agent comprising only an α-glucosidase inhibitor in combination with a non-sulfonylurea insulinsecretagogue as active ingredients is useful as an agent for the prophylaxis or treatment of diabetes and the like.

Oxazolidinedione derivatives, their production and use field of the invention

Tnf- alpha inhibitors

TNF- inhibitors containing at least one compound selected from among serivastatin, atorvastatin, simvastatin, pravastatin, itavastatin and (+)-(3R,5S)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonylamino)pyrimidin-5-yl]-3,5-dihydroxy-6(E)-heptenoic acid and salts thereof which have sufficiently favorable properties as drugs, for example, exhibiting excellent preventive and therapeutic effects on TNF-α-associated diseases such as inflammatory diseases without showing any side effects.

5-MEMBER N-HETEROCICLIC COMPOUNDS WITH HYPOGLUCEMIC AND HYPOLIPIDEMIC ACTIVITY.

Un compuesto de la **fórmula** en la que R1 representa 1) un grupo hidrocarbonado seleccionado entre el grupo que consiste en un grupo hidrocarbonado alifático que tiene 1 a 8 átomos de carbono, un hidrocarbonado alicíclico que tiene 3 a 7 átomos de carbono, un grupo hidrocarbonado alicíclico-alifático que tiene 4 a 9 átomos de carbono, un grupo hidrocarbonado aromático-alifático que tiene 7 a 13 átomos de carbono, y un grupo hidrocarbonado aromático que tiene 6 a 14 átomos de carbono, o 2) un grupo heterocíclico monocíclico de 5 a 7 miembros que contiene 1 a 4 heteroátomos seleccionados entre átomos de oxígeno, átomos de azufre y átomos de nitrógeno, además de átomos de carbono, como átomos constituyentes de anillo; o grupo heterocíclico condensado que resulta de la condensación de dicho grupo heterocíclico monocíclico de 5 a 7 miembros con un anillo de 6 miembros que contiene 1 a 2 átomos de nitrógeno, anillos de benceno o un anillo de 5 miembros que contiene 1 átomo de azufre, cada uno de 1) y 2) anteriormente mencionados puede tener 1 a 5 sustituyentes seleccionados entre el grupo que consiste en (i) un átomo de halógeno, (ii) grupo nitro, (iii) un grupo hidrocarbonado alifático de cadena recta o ramificada que tiene 1 a 15 átomos de carbono. A compound of the ** formula ** in which R 1 represents 1) a hydrocarbon group selected from the group consisting of an aliphatic hydrocarbon group having 1 to 8 carbon atoms, an alicyclic hydrocarbon having 3 to 7 carbon atoms , an alicyclic-aliphatic hydrocarbon group having 4 to 9 carbon atoms, an aromatic-aliphatic hydrocarbon group having 7 to 13 carbon atoms, and an aromatic hydrocarbon group having 6 to 14 carbon atoms, or 2) a group 5 to 7 membered monocyclic heterocyclic containing 1 to 4 heteroatoms selected from oxygen atoms, sulfur atoms and nitrogen atoms, in addition to carbon atoms, as ring constituent atoms; or condensed heterocyclic group resulting from the condensation of said 5- to 7-membered monocyclic ...

Multisegment collimator

(57)【要約】本公報は電子出願前の出願データであるた め要約のデータは記録されません。

Five-membered heterocyclic alkanoic acid derivative

A compound represented by the general formula (I) [wherein R1 represents an optionally substituted five-membered heterocyclic group; X represents a bond, etc.; Q represents a C¿1-20? divalent hydrocarbon group; Y represents a bond, etc.; ring A represents an aromatic ring optionally having one to three substituents; Z represents -(CH2)n-Z?1¿- (n is an integer of 0 to 8 and Z1 represents a bond, etc.), etc.; ring B represents a five-membered heterocycle optionally having one to three substituents; W represents a C¿1-20? divalent saturated hydrocarbon group; and R?2¿ represents -OH, etc.]; or a salt of the compound. A medicinal composition containing the compound or salt is useful as a preventive/remedy for diseases such as diabetes.

Function regulator for retinoid relative receptor

The present invention provides a retinoid-related receptor (except retinoic acid receptors) function regulatin agent comprising a compound represented by the formula: wherein one of R 1 and R 2 is an optionally substituted monocyclic aromatic hydrocarbon group or an optionally substituted monocyclic aromatic heterocyclic group containing one heteroatom, and the other is a hydrogen atom and the like; B is a 5- or 6-membered heterocycle (except 1,3-azole); A is an optionally substituted aromatic hydrocarbon group or an optionally substituted aromatic heterocyclic group; and R 3 is a hydrogen atom and the like, or a salt thereof, which is useful as an agent for the prophylaxis or treatment of diabetes mellitus, hyperlipidemia, impaired glucose tolerance or the like.

Pharmaceutical preparation

The present invention relates to a pharmaceutical preparation containing an insulin response-intensifying agent, with the exclusion of troglitazone, in combination with biguanide. Disclosed is also the use of the insulin response intensifying agent, with the exclusion of troglitazone, in combination with biguanide for preparing a pharmaceutical composition intended for prophylaxis or treatment of patients suffering from diabetes mellitus.

Retinoid-associated receptor function regulating agent

Retinoid-associated receptor regulators containing 1,3-azole derivatives represented by general formula (I) or salts thereof wherein R1 represents optionally substituted aromatic hydrocarbyl or heteroaryl; R2 represents hydrogen or optionally substituted hydrocarbyl; X represents O, s or -NR4-; A represents optionally substituted aromatic hydrocarbyl or heteroaryl; and R3 represents -OR5 or -NR6R7. These products are usable as, for example, preventives and remedies for diabetes, etc.

5-membered n-heterocyclic compounds with hypogylcemic and hypolipidemic activity

A compound of formula (I) F wherein R1 represents a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; x represents a bond, an oxygen atom, a sulfur atom, or a group of the formula: -CO-, -CS-, -CR4(OR5)- or -NR6- wherein each of R?4 and R6¿ represents a hydrogen atom or a hydrocarbon group which may be stubstituted, R5 represents a hydrogen atom or a protective group for a hydroxyl group; m represents an integer of 0 to 3; Y represents an oxygen atom, a sulfur atom, or a group of the formula: -SO-, -SO¿2?-, -NR7-, -CONR7- or -NR?7¿CO- wherein R7 represents a hydrogen atom or a hydrocarbon group which may be substituted; ring A represents an aromatic ring which may further have 1 to 3 substituents; n represents an integer of 1 to 8; ring B represents a nitrogen-containing 5-membered hetero ring which may further be substituted by an alkyl group.

ALPHA GLUCOSIDASE INHIBITOR FOR PROMOTING CALCIUM ABSORPTION.

Alpha-glucosidase inhibitor is provided as a promoter of calcium absorption in mammals. The examples of the inhibitor are shown by the formula; <CHEM> wherein A stands for a C1-C10 acyclic hydrocarbon group which may be substituted by hydroxyl, phenoxy, thienyl, furyl, pyridyl, cyclohexyl or phenyl group which itself may be further substituted, a C5-C6 cyclic hydrocarbon group which may be substituted by hydroxyl, hydroxymethyl, methyl or amino group, or a sugar residue. There is also provided a calcium preparation which contains an alpha -glucosidase inhibitor and a calcium source.

5-Membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity.

Pharmaceutical composition for use in treatment ofdiabetes

Agent regulating function of receptor connected with retinoids

Farmaceutický prostředek regulující funkci receptoru. souvisejícího s retinoidy, který obsahuje 1,3-azolový derivát obecného vzorce I, v němž R1 znamená aromatickou * uhlovodíkovou skupinu nebo aromatickou heterocyklickou skupinu, z nichž každá může být substituována, R2 znamená atom vodíku nebo popřípadě substituovanou uhlovodíkovou skupinu, X znamená atom kyslíku, atom síry nebo skupinu obecného vzorce -NR4-, v němž R4 znamená atom vodíku nebo popřípadě substituovanou alkylovou skupinu, A znamená aromatickou uhlovodíkovou skupinu nebo aromatickou heterocyklickou skupinu, z nichž každá může být substituovaná, R-znamená skupinu obecného vzorce -OR5, v němž R5 znamená atom vodíku nebo popřípadě substituovanou uhlovodíkovou skupinu, nebo skupinu obecného vzorce -NR6R7, v němž R6 a R7 znamenají stejnou nebo různou skupinu a každý znamená atom vodíku nebo popřípadě substituovanou uhlovodíkovou skupinu, nebo R6 a R7 mohou společně s přilehlým atomem dusíku tvořit kruh; nebo jeho sůl. Tento prostředek je zejména vhodný pro léčbu či prevenci diabetů, hyperlipidemie či zhoršené tolerance na

THIAZOLIDINDIONE DERIVATIVES, THEIR PRODUCTION AND USE

Pharmazeutisches mittel zur behandlung von diabetes

Pharmaceutical composition

Verwendung von pioglitazone zur verbesserung der ketose und der azidose

Cukorbetegség elleni (antidiabetikus) hatású gyógyászati készítmény

Pharmazeutische zubereitung enthaltend pioglitazone und glimepiride zur verwendung in der behandlung von diabetes

Alkansäurederivate, verfahren zu deren herstellung und deren verwendung

Oxyiminoalkansäure derivate mit hypoglykämischer und hypolipidemischer wirkung

Thiazolidindione derivate, ihre herstellung und verwendung

Oxazole derivate,ihre herstellung und verwendung

Oxazolidindion-derivate, ihre herstellung und verwendung

Fünfgliedrige n-heterocyclen mit hypoglykämischer und hypolipidemischer wirkung

開放型トンネル掘削機およびトンネル掘削方法

【課題】浅い深度のトンネルであっても地表面沈下を発生させない開放型の簡単な構造とすることで、掘削機のコストを低減することができる。 【解決手段】トンネル掘削機１は、筒状をなす外殻スキンプレート２と、外殻スキンプレート２内に独立してトンネル軸方向に進退可能に設けた複数台の小断面掘削機１０とを備えている。小断面掘削機１０は、小断面スキンプレート１１と、その小断面スキンプレート１１の切羽側開口部１０ａに開閉可能に設けた開閉蓋１４と、小断面スキンプレート１１の内側でトンネル軸方向に進退可能に設けられるとともに開閉蓋１４が開いた状態で開放された切羽側開口部１０ａより切羽の地山を掘削するための掘削機構２０とを有している。 【選択図】図１

薄板片及び薄板片溶接用構造

【課題】 変形を防止すると同時に溶接し易い薄板片、及び隣接する二つの前記薄板片の溶接が容易となる薄板片溶接用構造を提供する。 【解決手段】 薄板片本体と、断面略Ｌ字状で、Ｌ字の空間部が前記薄板片本体の端部の方向に向くようにかつこの端部の近傍でこの端部に沿うように前記薄板片本体に固定した補強部材とを有する。前記薄板片本体は、孔を有する突起部を有し、前記補強部材は、前記突起部を通す第一の貫通孔を前記補強部材の横部に有し、前記貫通孔に前記突起部を通した後に前記突起部の孔に第一の嵌め込み部材を嵌め込んで前記補強部材を前記薄板片本体に固定したものである。 【選択図】 図２

Oksiiminoalkanoik asit türevleri.

Retinoid ile ilgili reseptör fonksiyonu düzenleyici madde

掘削装置

【課題】掘削面を広範囲に掘削可能で、狭隘な場所や複雑な掘削形状でも確実に掘削できる掘削装置を提供すること。 【解決手段】掘削面に対して平行な掘削軸を有し、前記掘削軸の周面に掘削刃を備える掘削手段と、前記掘削軸と平行する揺動軸を有し、前記揺動軸を支点として前記掘削手段を揺動可能に構成した揺動手段と、前記掘削軸に直交する反転軸を有し、前記反転軸を支点として前記掘削手段を回動可能に構成した反転手段と具備してなる掘削装置である。 【選択図】図１

岩盤空洞内で行う横形円筒タンクの形成方法及び横形円筒タンクのタンク部品の構築用装置

【課題】岩盤空洞内においても横形円筒タンクを作業手順良く安全に形成することが出来る岩盤空洞内で行う横形円筒タンクの形成方法を提供する。また、横形円筒タンクのタンク部品の構築用装置を提供する。 【解決手段】岩盤空洞３内で行う横形円筒タンク１の形成方法において、架台２５を前記岩盤空洞３内に形成する第１ステップと、架台２５の上で薄板材を組み立てて円筒部を有するタンク部品を形成する第２ステップと、架台２５を前方に移動させてタンク部品を前方に移動させる第３ステップとを有する。 【選択図】図１

自走コンベア式作業機

【課題】前後のローラを介してベルトを支持する本体フレームの剛性が十分に確保される自走コンベア式作業機を提供する。 【解決手段】搬送物を搬送する自走コンベア式作業機であって、搬送物を積載する無端状のベルト３０と、このベルト３０が掛け回されてその回転によりベルト３０を循環させる前後のローラ３１、３２と、ベルト３０及び前後のローラ３１、３２を搬送する走行装置１２と、前後のローラ３１、３２及び走行装置１２を支持する本体フレーム５０と、で構成され、この本体フレーム５０は、前後のローラ３１、３２の左右端にそれぞれ設けられて前後のローラ３１、３２を連結する左右のサイドメンバ５１と、ベルト３０の循環経路より外側に配置されて左右のサイドメンバ５１の前後端どうしをそれぞれ連結する前後のクロスメンバ５５、５７と、を備える構成とする。 【選択図】図２

Driving mechanism of simulation sample for ct scanner

Pharmazeutische zubereitung zur verwendung in der behandlung von diabetes

Benzofuranderivate zur Verwendung als hypoglycemische und hypolipidemische Wirkstoffe

5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity.

建築設備図面作成装置

(57)【要約】 【課題】 建築設備系統図の作成作業の省力化を図る。 【解決手段】 複数階からなる建築物に設置された機器 が接続部材に接続されている機器間の構成を示す建築設 備系統図を作成する場合、作成済の建築設備平面図を、 他図面参照部８８により、ディスプレイ２４に表示す る。そして、属性複写部６８により、表示中のて建築設 備平面図から建築設備系統図の作図領域へ、負荷情報を 複写する。それから、負荷集計部７８により、接続部材 に接続された全機器の負荷情報を集計する。この集計さ れた負荷情報に基づいて、サイズ決定部７９により、接 続部材のサイズを決定する。これにより、建築設備系統 図の作成効率が向上する。

Alpha-glucosidaseinhibitor zur foerderung der calciumabsorption.

Derivados de oxazol, su produccion y uso.

LA INVENCION SE REFIERE A UN COMPUESTO NUEVO DE FORMULA (I), DONDE R 1 ES UN ATOMO DE HALOGENO, UN GRUPO HETEROCIC LICO OPCIONALMENTE SUSTITUIDO, UN GRUPO HIDROXILO, TIOL O AMINO; A ES UN GRUPO ACILO OPCIONALMENTE SUSTITUIDO, UN GRUPO HETEROCICLICO OPCIONALMENTE SUSTITUIDO, UN GRUPO HIDROXILO OPCIONALMENTE SUSTITUIDO, O UN GRUPO CARBOXILO OPCIONALMENTE ESTERIFICADO O AMIDADO; B ES UN GRUPO AROMATICO OPCIONALMENTE SUSTITUIDO; Y ES UN GRUPO HIDROCARBONADO ALIFATICO DIVALENTE, O UNA SAL DEL MISMO. DICHOS COMPUESTOS TIENEN UN EXCELENTE EFECTO PROMOTOR DE LA SECRECION DE INSULINA Y DEPRESOR DEL AZUCAR EN SANGRE, Y SON UTILES COMO AGENTES PARA EL TRATAMIENTO DE LA DIABETES.

掘削機

(57)【要約】 【課題】 アンダーパス工事における非開削工法による 掘削作業をより機能的に実行し得るのはもちろんのこ と、メンテナンスに関して手間が掛らず、さらに、粘性 が区々となる礫の円滑な搬出を可能にする。 【解決手段】 切羽に対向するように配在されるカッタ ヘッド１と、このカッタヘッド１を先端に連設する中空 らせんの搬送装置２とを有してなり、中空らせんの搬送 装置２が大容量の礫の搬送を可能にしてなる。

Benzofuranderivate zur verwendung als hypoglycemische und hypolipidemische wirkstoffe

Alpha-glucosidaseinhibitor zur foerderung der calciumabsorption.

無限軌道走行装置及び走行車

【課題】転倒しても走行を続けられる無限軌道走行装置及び走行車を提供すること。 【解決手段】回転自在な複数の転輪５に巻き回される無端状の軌道体４によって車体２を走行させる無限軌道走行装置３であって、軌道体４の内側に設けられ、各転輪５のそれぞれを支持するリンク機構１０と、このリンク機構１０を駆動して、各転輪５を介して軌道体４の外形を変形させる駆動部とを備える構成とする。 【選択図】図１

5-membered heterocycle derivatives